 |
July-December 2016 Volume 2 | Issue 2
Page Nos. 73-129
Online since Tuesday, December 20, 2016
Accessed 161,105 times.
PDF access policy Full text access is free in HTML pages; however the journal allows PDF accesss only to users from developing countries and paid subscribers.
EPub access policy allows EPub access only to users from developing countries and paid subscribers.
|
| |
|
Show all abstracts Show selected abstracts Add to my list |
|
EDITORIAL |
|
|
|
Purified protein derivative immunotherapy for viral warts and interpretation of tuberculin skin tests and interferon gamma release assay for diagnosis of tuberculosis in India
|
p. 73 |
Sushil Pande, Anil Sontakke, BO Tayade DOI:10.4103/2455-3972.196165 |
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (1) ] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
REVIEW ARTICLE |
 |
|
|
 |
Apremilast: A dermatologic perspective  |
p. 75 |
Aditya Kumar Bubna DOI:10.4103/2455-3972.196166 Apremilast is an oral phosphodiesterase 4 inhibitor, now approved by the Food and Drug Administration in the management of psoriatic arthropathy (PsA). As biologic therapy is associated with significant amounts of adverse effects, newer treatment options with an efficacious outcome, sans the toxicity, is something all clinicians would implement readily in their therapeutic regimens. Apremilast is one such drug which has shown promise in the management of psoriasis, PsA, and a few other dermatologic disorders. This review will throw light on the dermatologic perspective regarding apremilast. |
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (7) ] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
ORIGINAL ARTICLES |
 |
|
|
|
Role of folic acid supplementation in reducing side effects of oral methotrexate in patients of psoriasis: A study |
p. 83 |
Tulika Rai, Satyendra Kumar Singh DOI:10.4103/2455-3972.196167 Background: Methotrexate (MTX) has been used for the treatment of severe psoriasis for more than 50 years. MTX use can be associated with many side effects, and folic acid is supplemented to reduce these side effects. MTX can be given orally or parenterally. Materials and Methods: In this study, a total of 81 patients of severe psoriasis were given 15 mg/week of MTX orally, and side effects were noted at each visit. Results: A total of 36 patients developed side effects, of which ten patients were discontinued due to the development of serious side effects. Remaining 26 patients developing nonserious side effects were given folic acid 5mg/day on non-MTX days and continued with 15 mg/week of MTX therapy. They were further evaluated for any improvement in side effects. Folic acid supplementation was associated with improvement in gastrointestinal and mucosal side effects in 17 out of 26 patients. Conclusion: Therapeutic effects were not compromised in all these patients after initiation of folic acid therapy. We recommend the supplementation of folic acid 5 mg/day in all patients of psoriasis who are receiving 15 mg/week of MTX therapy.
|
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta |
|
|
|
|
|
 |
Different treatment modalities in the treatment of childhood lichen planus |
p. 87 |
Urmila Nischal, Vidya Kharkar DOI:10.4103/2455-3972.196168 Introduction: Although rarely described in the Western literature, childhood lichen planus (LP) is noticed much more frequently in the Indian subcontinent. Oral and potent topical corticosteroids commonly used for the treatment of childhood LP can result in significant side effects. Methods: In a open non-randomized follow up study of 49 children, various treatment modalities were tried based on inclusion exclusion criteria. Results: A total of 49 children had generalized or localized LP, of which 5 patients did not complete prescribed therapy. Out of 25 patients who were started with oral dapsone, a total of 20 patients completed therapy. These patients showed a significant improvement showing relief from itching associated with flattening of lesions. Complete response was seen in three-fourth of metronidazole-treated patients by 20 weeks. Remaining 11 patients who were treated oral, topical, or intralesional therapy also showed improvement as predicted. Dapsone and metronidazole therapy did not result in any side effects in this study. Conclusion: Dapsone can be utilized as an effective steroid-sparing agent in the treatment of childhood LP. |
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (1) ] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
BRIEF CASE REPORT |
 |
|
|
 |
Acitretin therapy for inflammatory linear verrucous epidermal nevus |
p. 93 |
Sharad D Mutalik, Yashashree Rasal DOI:10.4103/2455-3972.196169 Acitretin has been commonly used in the treatment of keratinization disorders due to its anti-inflammatory and anti-proliferative properties. ILVEN is a rare form of epidermal nevus with an early age of onset usually presenting as a localized itchy linear plaque resistant to treatment. The treatment of ILVEN aims at providing symptomatic and cosmetic improvement. We present two cases of ILVEN with solitary lesions treated with acitretin, with both patients showing remarkable reduction of the lesions with long term remission. |
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
CASE REPORTS |
 |
|
|
 |
Hailey-Hailey disease: Botulinum toxin treatment |
p. 96 |
Kathia Werlang Donadel, Matheus Werlang Donadel, Rafael Werlang Donadel, Bruna Orquiza dos Santos DOI:10.4103/2455-3972.196170 Hailey-Hailey disease, also known as familial chronic benign pemphigus, is characterized by flaccid blisters and erosions, especially in the axillary and inguinal areas. Friction associated with local factors such as heat, moisture, microbial colonization, and secondary infections induce the typical appearance of the lesions, especially in intertriginous areas. Traditionally, the treatment is done with corticosteroids associated with topical or systemic antibiotics. We report the case of a patient with the disease presenting in the inguinal region, which has made use of different conventional drug treatments for 20 years without results. Treatment with application of botulinum toxin type A showed a significant improvement after about 20 days. The satisfactory response has been linked to decreased local sweating caused by botulinum toxin. which would lead to a less local irritation factors and lower colonization of microrganisms. |
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta |
|
|
|
|
|
 |
Nicolau syndrome: A rarely seen iatrogenic fatal cutaneous reaction following intramuscular diclofenac injection |
p. 99 |
Anup Kumar Tiwary, Rohit K Aggarwal DOI:10.4103/2455-3972.196171 Nicolau syndrome, also known as embolia cutis medicamentosa or livedoid dermatitis, is a rare cutaneous adverse drug reaction seen at the site of injection of some particular drugs. It was first reported by Freudenthal in 1924 and Nicolau in 1925 as an adverse effect of bismuth salts used in syphilis. Typically, this syndrome is clinically manifested by intense burning or stabbing pain at the site of injection and retiform hemorrhagic patches with or without vesiculations and ulceration with a variable degree of tissue necrosis. To the best of our knowledge, <50 cases of Nicolau syndrome have been reported in medical literature which occurred following intramuscular administration of diclofenac sodium. Here, we report a 26-year-old female typically presenting with pathognomic signs and symptoms of NS after taking intramuscular injection of diclofenac. |
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (1) ] [Sword Plugin for Repository]Beta |
|
|
|
|
|
 |
Sorafenib-induced pemphigus vulgaris |
p. 102 |
Ajay Deshpande DOI:10.4103/2455-3972.196172 Sorafenib is a tyrosine kinase inhibitor approved for the treatment of primary kidney cancer, advanced primary hepatocellular carcinoma and radioactive iodine-resistant advanced thyroid carcinoma. Sorafenib is known to cause milder cutaneous side effects such as maculopapular rash and serious cutaneous drug reactions such as desquamation of the skin, hand-foot syndrome Stevens-Johnsons syndrome and toxic epidermal necrolysis. We report a histopathologicaly proved case of pemphigus vulgaris caused by sorafenib. |
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
LETTERS TO EDITOR |
 |
|
|
|
Tuberculin purified protein derivative immunotherapy in the treatment of viral warts |
p. 105 |
Mahmood Dhahir Al-Mendalawi DOI:10.4103/2455-3972.196173 |
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta |
|
|
|
|
|
 |
Sebaceous hyperplasia: Treatment with combination of oral isotretinoin and salicylic acid chemical peeling  |
p. 106 |
Sushil Kakkar, Prafulla K Sharma DOI:10.4103/2455-3972.196174 |
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta |
|
|
|
|
|
 |
Tretinoin in microsphere technology increases the sphere of efficacy in verruca plana |
p. 108 |
C Madura, BS Chandrashekar, Samipa Samir Mukherjee, R Pavan Raj DOI:10.4103/2455-3972.196176 |
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta |
|
|
|
|
|
 |
Levetiracetam-induced maculopapular rash: A rare side effect |
p. 109 |
Mahesh M Unni, Dinesh Verma, Ruikar Devashish DOI:10.4103/2455-3972.196204 |
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (1) ] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
Levamisole-induced drug fever |
p. 111 |
Lalit Kumar Gupta, Manisha Balai, Ashok Kumar Khare, Ajit Singh, Asit Mittal DOI:10.4103/2455-3972.196217 |
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta |
|
|
|
|
|
 |
Azacitidine-induced leukocytoclastic vasculitis |
p. 112 |
Snehal Lunge, Rohan Bhise DOI:10.4103/2455-3972.196221 |
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (1) ] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
TABLE |
 |
|
|
|
Drug-induced fever versus infection-induced fever  |
p. 115 |
Sagar Jugtawat, Bhagyashri Daulatabadkar, Sushil Pande DOI:10.4103/2455-3972.196224 |
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
MANAGING A SIDE EFFECT |
 |
|
|
 |
How to manage a side effect: Dapsone-induced methemoglobinemia |
p. 117 |
Bhushan Madke, Piyush Kumar, Poonam Kabra, Adarsh Lata Singh DOI:10.4103/2455-3972.196225 |
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (1) ] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
VIVA VOCE |
 |
|
|
|
Viva Voce on omalizumab |
p. 121 |
Kiran Godse, Resham Vasani DOI:10.4103/2455-3972.196227 |
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (1) ] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
CASE BASED LEARNING |
 |
|
|
 |
Fixed drug eruption secondary to doxycycline |
p. 124 |
Bhavana Ravindra Doshi, NS Chougule, VA Belgaumkar, RB Chavan DOI:10.4103/2455-3972.196229 |
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
WHAT’S IN NEWS |
 |
|
|
|
News from regulatory corner |
p. 128 |
DOI:10.4103/2455-3972.196230 |
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta |
|
|
|
|
|